CRUK Consent Forms – Bladder cancer immunotherapy regimens

Urology – Bladder cancer immunotherapy regimens have been updated and added to the CRUK website.

A new form for Nivolumab has been added.

Revalidation of the remaining regimen specific consent forms are in progress and will be updated in due course.

All forms can be found at www.cruk.org/sact_consent.

Please share this update within your clinical teams or forward to the relevant lead cancer clinician for your organisation.

Any questions, please do let me know.

Best wishes,

Alia

Alia Nizam |Specialist Oncology Pharmacist. CRUK – Information Lead|

Latest News

By BOPA Executive Committee on 30th October 2026

Publication of Pharmaceutical Technology and Pharmacology of Parenteral Oncology Drugs

We are delighted to recognise the recent publication of Pharmaceutical Technology and Pharmacology of Parenteral Oncology Drugs, a new book bringing together expertise from oncology pharmacy professionals across the world.…

Read article
By BOPA Executive Committee on 30th October 2026

Acute and Supportive Oncology Clinical Consensus Statement

BOPA welcomes the Acute and Supportive Oncology Clinical Consensus Statement, to which we were pleased to contribute. It will be a benchmark for the sector, bringing direction and consistency as…

Read article
By BOPA, COSA, CAPhO & ISOPP on 13th October 2026

International Debate Webinar: Eastern and Western Medicine Can Co-exist – part of London Global Cancer Week 2026

Monday 2 November 2026 | 21:00 GMT (check your local time) Part of London Global Cancer Week 2026 Can Eastern and Western medicine co-exist in modern cancer care? Or do…

Read article
By Joseph Williams on 8th October 2026

BOPA 2026 Mentioned in Pharmaceutical Journal

Invest in aseptic services for future of specialised medicines, says chief pharmacist – The Pharmaceutical Journal Aseptic facilities are “absolutely essential” for hospitals to be involved in clinical trials and…

Read article